Background {#Sec1}
==========

Filamins are large actin-binding proteins that stabilize delicate three-dimensional actin webs and link these to cellular membranes. They integrate cellular architectural and signalling functions and are essential for fetal development and cell locomotion \[[@CR1]\].

Filamin A (FLNA) is the first actin filament cross-linking protein identified in non-muscle cells. Mutations in the X-linked gene encoding filamin A (at chromosomal locus Xq28) have been reported to cause a wide range of human diseases, such as cerebral periventricular nodular heterotopia (PVNH), cardiac valvular disease and skeletal anomalies to a variable degree \[[@CR2]--[@CR10]\]. Airway anomalies such as tracheal stenosis or tracheobronchomalacia have also been documented and recently lung involvement has been reported \[[@CR2], [@CR11]--[@CR22]\].

*FLNA*-related PVNH is a malformation of cortical development characterized by bilateral near-contiguous ectopic neuronal nodules found along the lateral ventricles \[[@CR6], [@CR7]\]. It may be isolated or associated with other brain malformations, including hippocampal malformation and cerebellar hypoplasia, bilateral fronto-perisylvian or temporo-parietooccipital polymicrogyria, hydrocephalus and microcephaly. In a smaller group of patients, PVNH was found to be associated with non-neurologial defects including Ehlers--Danlos syndrome, frontonasal dysplasia, limb abnormalities, ambiguous genitalia and fragile-X syndrome. Finally, several distinct subgroups of patients have been identified with an unusual PVNH presentation, including a micronodular appearance, unilateral distribution and laminar or ribbon-like shapes \[[@CR23]\]. Progressive lung involvement in *FNLA*-related PVNH has been reported in a limited number of cases \[[@CR2], [@CR11]--[@CR22]\] and emphysematous lesions in the pulmonary parenchyma are the characteristic findings of this mutation.

We report the case of a male infant with a novel pathogenic variant of the *FLNA* gene mutation, who developed significant lung disease and in whom a periventricular nodular heterotopia was also diagnosed.

Case presentation {#Sec2}
=================

A 32 day old male infant was referred to our department, from another hospital, with acute respiratory distress syndrome and suspected congenital pulmonary malformation. The baby (fourth child of nonconsanguineous caucasian parents) was born by vaginal delivery at 37 weeks' gestation, with a weight of 3140 g. The first month of life was unremarkable. The family had no history of genetic or metabolic diseases or congenital disorders.

At admission, the physical examination confirmed respiratory distress, general hypotonia due to respiratory failure and fatigue, bilateral inguinal hernia and deformities of the lower limbs (*pes tortus congenitalis* and hip dysplasia).

A chest X-ray (Fig. [1](#Fig1){ref-type="fig"}) and computed tomography (CT) scan (Fig. [2](#Fig2){ref-type="fig"}, Panels a, b) showed severe hyperinflation of the apical segment of the left lung and mediastinal shift to the right. A presumptive diagnosis of congenital lobar emphysema (CLE), including the lower lobe was made. After the stabilization of the subject's respiratory conditions (non invasive respiratory support, fluid and electrolyte management, broad spectrum antibiotics, bronchodilatator), considering the inclusion of the superior lobe and the upper part of the lower lobe we decided to proceed with observation.Fig. 1Chest X-ray at admission shows left pulmonary areas of hyperinflation (see arrows)Fig. 2CT thorax at admission (Panels **a**, **b**) and two months later (Panels **c**, **d**). The arrows indicate the hyperinflation area. Panels a, c: axial position; Panel b, d: sagittal position

Two months later, the child's condition deteriorated with worsening in respiratory distress; the child was unable to maintain saturation even with oxygen support. CT-angiography (Fig. [2](#Fig2){ref-type="fig"}, Panels c, d) was ordered and revealed a severe lobar emphysema of the anterior to the apicoposterior segment of the left upper lobe, with displacement of mediastinal structures to the right and compression of the right structures. A subsegmental atelectasis and areas of air trapping in the apicoposterior segment of the left lower lobe were also noted. Angiography showed peripheral pulmonary vascular attenuation and central pulmonary artery enlargement.

Surgery included a left upper lobectomy and segmental resection of the left lower lobe. The histopathology report was consistent with a generalized lung growth abnormality with alveolar enlargement and simplification.

Following surgery, multiple attempts to extubate the infant failed and he had a persistent oxygen requirement. Chronic respiratory failure ensued with progressive worsening of the ventilatory performance, necessitating continuous mechanical ventilation, with gradual support parameter adjustments and tracheostomy at age 12 months.

After prolonged multidisciplinary discussion, the decision to perform a surgical thoracoscopic lung biopsy was made in order to obtain additional data on the pathological pulmonary features for prognostic predictions and therapeutic decisions. Histopathology revealed alveolar enlargement, perivascular and interstitial fibrosis and intra-alveolar hemorrhages (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Histological features. In Panel **a,** areas in blue and the arrows indicate the perivascular and interstitial fibrosis and intra-alveolar hemorrhages (Azan-Mallory coloration, magnification 10x). In Panel **b**, areas in brown (Tenascin, magnification 10x) indicate where Tenascin was overexpressed, highlighting the extensive parenchymal fibrosis. TNC localization in the normal lung was un-detectable; TNC is specifically and transiently expressed upon tissue injury and down-regulated when tissue repair or scarring is concluded \[[@CR38]\]

Genetic testing was performed during the course of clinical care, after obtaining informed consent. Next generation sequencing on genomic DNA was performed using the NimbleGen SeqCap Target Enrichment kit (Roche) designed to capture several genes involved in pulmonary surfactant protein deficiency and skeletal abnormalities. A library was prepared following the manufacturer's instructions and subsequently sequenced on an Illumina NextSeq550 instrument. Sequence data were carefully analyzed and the presence of all suspected variants were checked in the public databases (dbSNP, 1000 Genomes, and Exome Aggregation Consortium). The identified variants were confirmed by Sanger sequencing, following a standard protocol (BigDye® Terminator v3.1 Cycle Sequencing Kit,Life Technologies). No potentially causative variants were found in genes associated with cystic fibrosis, pulmonary surfactant protein deficiency or mutations in the *SETBP1* gene associated with Schinzel--Giedion syndrome (a rare autosomal dominant disorder that results in facial dysmorphism and organ and bone abnormalities).

Sequencing analysis showed a new mosaic frameshift variant, NM_001456.3: c.7391_7403del, p.Val2464Alafs\*5 in the *FLNA* gene that was not present in the maternal blood DNA. This variant has not been previously reported in individuals with FLNA-related disorders, but can be classified as likely pathogenic (Class 4) according to the ACMG guideline and it is expected to cause disease. It is not present in any public databases, dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>, 1000 Genomes Project (<http://www.internationalgenome.org/>), EVS (<http://evs.gs.washington.edu/EVS/>), ExAC (<http://exac.broadinstitute.org/>) and can be considered as a private variant.

The same mutation was identified in DNA from salivary and pulmonary mesenchymal stem cells of the patient \[[@CR24]\].

Brain magnetic resonance imaging (MRI) depicted PVNH (Fig. [4](#Fig4){ref-type="fig"}), although the patient was not suffering from any neurological symptoms at this stage.Fig. 4Brain MRI. Appearance of nodules (indicated by arrows) in periventricular grey matter heterotopia (images **b**, **e**, **d**), surrounding the left temporal horn and merging with the hippocampal cortex (image **c**). Supratentorial signal alterations with T2 and FLAIR hyperintense (images **a**, indicated by triangles) as in demyelinating lesions

At 14 months follow-up, the patient requires mechanical ventilation and artificial nutrition to maintain his growth. Epilepsy and other neurological manifestations were not recorded.

Discussion and conclusions {#Sec3}
==========================

Filamin A is an actin-linking protein that regulates cell shape and migration of many cell types, including neuronal, vascular and cutaneous cells \[[@CR15]\]. Filamin A is composed of three main functional domains: (1) a tandem N-terminal calponin-homology domain (CHD1 and CHD2), which confers F-actin binding properties; (2) 15 + 8 internally homologous Ig-like repeats separated by a short run with an unique sequence (hinge 1), important for flexibility; and (3) a second short run (hinge 2) followed by the C-terminal repeat 24, which are important for binding to a wide range of proteins and for dimerization \[[@CR25]\]. Null mutations in the *FLNA* gene, lead to defects in neuronal migration, vascular function and connective tissue integrity. In contrast, gain-of-function missense mutations in this same gene produce a spectrum of malformations in multiple organ systems, especially the skeleton \[[@CR26]\].

Here, we report the case of a male child in whom a new mosaic loss-of-function variant of the *FLNA* gene c.7391_7403del; p.Val2464Alafs\*5 was found by next generation sequencing, resulting in significant lung disease characterized by emphysematous lesions and perivascular and interstitial fibrosis. The mutant allele frequency of this variant is estimated to be around 36% considering the numbers of sequence reads of the mutant and the wildtype alleles. This 13 bp deletion is predicted to result in a truncated protein that lacks the hinge 2 domain and repeat 24 probably leading to a loss of binding and dimerization ability that is essential for the FLNA function.

This report confirms an association between a *FLNA* gene mutation and lung disease. PNVH was observed and limb deformities were also present. There are 25 previous case reports in the literature on FLNA-related disorders with the pulmonary phenotype (Table [1](#Tab1){ref-type="table"}) \[[@CR2], [@CR9], [@CR13]--[@CR22]\]. Lung diseases are associated with documented PNVH in 84% of the reviewed cases. The presence of cardiac co-morbidities, such as patent ductus arteriosis, valvular disease and aortic root dilatation, have also been reported \[[@CR2]--[@CR10], [@CR13]--[@CR15], [@CR18]\]. Mutations in the filamin A gene are inherited in an X-linked (Xq28) dominant manner, with perinatal lethality in most males, whereas in female patients the prognosis depends on the severity of the associated cardiovascular abnormalities \[[@CR20]\]. Of the previously published cases 21/25 (80%) were female (Table [1](#Tab1){ref-type="table"}). Perinatal lethality occured in six of these reported cases (24%; 5 females and 1 male); in all cases, cardiopathies were also found \[[@CR2]--[@CR10], [@CR13]--[@CR15], [@CR18]\]. As reported in Table [1](#Tab1){ref-type="table"}, a large spectrum of *FLNA* mutations are detected in patients with pulmonary disease, including missense mutations \[[@CR9], [@CR13], [@CR14], [@CR19]\], nonsense mutations \[[@CR2], [@CR20]\], deletions \[[@CR13], [@CR15], [@CR16], [@CR21]\], duplications \[[@CR13], [@CR14], [@CR18], [@CR21]\], truncating mutations \[[@CR17], [@CR21]\], and frameshift mutations \[[@CR14]\].Table 1Previous reports on *FLNA* gene variants associated with severe lung disordersSexMutationPrincipal clinical featuresCT scanGestational age (weeks)Age at presentationSurgeryDocumented PNVHOutcomeGerard-Blanluet et al., 2006 \[[@CR19]\]Male twins\*Missense mutation c.7922C \> T (p.Pro2641Leu)Severe bronchopulmonary dysplasia (BPD)Not provided2626 weeksNoneYesDeath of 1 infant at 8 mo; Follow-up until age 6 years (intercurrent respiratory infection)\*same familyFemale\*Missense mutation c.7922C \> T (p.Pro2641Leu)Severe BPDNot provided2424 weeksNoneYesFollow-up until age 2.5 yearsDe Wit et al., 2011 \[[@CR9]\]FemaleMissense mutation c.220G \> A (p.Gly74Arg)Lobar emphysema (right middle lobe); bronchomalacia of right bronchial tree; frequent respiratory infections.Severe lobar emphysema of right middle lobe; displacement of mediastinal structuresterm3 monthsLobectomy (right middle lobe)YesWeaned from oxygen at 1 year, 7 monthsMasurel-Paulet et al. 2011 \[[@CR2]\]MaleMosaic nonsense mutation c.994delG (p.Lys331\*)Progression to severe lung diseaseCongenital lobar emphysema;term3 monthsSubtotal left upper lobectomyYesAge 6 years. Supplemental oxygen during sleepClapham et al., 2012 \[[@CR21]\]Female3′ *FLNA* deletion sparing first exonPulmonary emphysema involving multiple lobesNot provided392 monthsNoneYesDeath at 7 monthsFemale3′ *FLNA* deletion and 5'*FLNA* duplicationApical bullae of lungNot providedNot providedNDNDYesNot providedFemaleDeletion entire *FLNA* geneLobar emphysemaNot providedNot providedNDNDYesNot providedReinstein et al., 2013 \[[@CR22]\]Female (case F3)Truncating mutation c.2193C \> A (p.Tyr731\*)Pulmonary hypertension, focal hyperinflation with minimal patchy atelectasisNot providedNot provided6 yearsNDYesNot providedLord et al., 2014 \[[@CR17]\]FemaleTruncating mutation c.5683G3 \> T (p.Gly1895\*)Progression to severe lung diseaseCystic pulmonary lesions;3624 daysnoneYesWeaned from oxygen at 22 monthsLange et al., 2015 \[[@CR20]\]Male (case 29)Mosaic non sense mutation c.7055-7070delCTTTTGCAGTCAGCCT (p.Ser2352\*)Severe progressive obstructive lung diseaseNot providedND38 yearsConsideration of lung transplantationYesNot providedEltahir et al., 2016 \[[@CR18]\]FemaleDuplication c.3153dupC (p.Val1052Argfs\*17)Progressive lung diseaseLower lobe airspace disease, hyperinflation (right middle and left upper lobes)362 monthsPDA ligationNot performedDeath at 15 monthsShelmerdine et al., 2017 \[[@CR13]\]FemaleDeletion c.88delG (p.Ala30Profs\*28)Progressive lung diseaseLeft upper lobe and lower inflation; coarse septal thickening36 + 53 monthsPDA ligationNot performedDied at 9 monthsFemaleDuplication c.6496dupA (p.lle2166Asnfs\*3)Multiple episodes of intercurrent pulmonary infectionsRight upper and middle lobe over-inflation; coarse septal thickening; lower lobe atelectasisterm7 monthsRigh upper lobectomy, PDA ligationYesAge 4 yearsFemaleMissense mutation c.1528G \> A (p.Ala510Thr)Meconium aspirationRight upper and left upper lobe over-inflation; coarse septal thickening; Lower lobe atelectasis40 + 4At birthNoneNot performedAge 3 years. Therapy with bronchodilatatorFemaleDeletion c.2190_2193delTTAC (p.Tyr731Alafs\*10)Viral infectionsRight upper and middle, left upper lobe over-inflation; Coarse septal thickening; Lower lobe atelectasis383 monthsNoneNot performedAge 6 years. Supplementary oxygen supportBurrage et al., 2017 \[[@CR14]\]FemaleDuplication c.4596dupG (p.Ser1533Glufs\*12)Progressive lung diseaseIn all patients, severe pulmonary hyperinflation and hyperlucency with peripheral pulmonary vascular attenuation with parahilar and dependent lower lobe atelectasis and central pulmonary artery enlargement.\
In all patient, pulmonary arterial hypertension was also diagnosed.392--4 monthsPDA ligationYesLung transplantation in all.\
Five survivors at 19 months, 3 years, 4 years, 5.1 years, and 11.3 years respectively, post- follow-up. One died at 3 yearsFemaleMissense mutationc.5290G \> A (p.Ala1764Thr)Progressive lung disease40neonatalPDA ligationYesFemaleDuplication c.4446_4447dupAT (p.Leu1483Tyrfs\*19)Progressive lung disease38neonatalPDA ligationYesFemaleDuplication c.4617_4618delGC (p.Leu1540Alafs\*4)Progressive lung disease34neonatalPDA ligationYesFemaleDuplication c.6585dupT (p.Pro2196Serfs\*3)Progressive lung disease39neonatalPDA ligationYesFemaleMissense mutation c.2807A \> G (p.Lys936Arg)Progressive lung disease38neonatalPDA ligationYesKinane et al. 2017 \[[@CR15]\]FemaleDeletion c.6577delC (p.Arg2193Alafs\*14)Diffuse pulmonary abnormalitiesGround glass opacities, area of hyperacration, pulmonary hypertension3930 dayPDA ligationYesSasaki et al. 2018 \[[@CR16]\]FemaleDeletion c.1709_1712del (p.Val570Alafs\*105)Progressive lung diseaseDiffuse bilateral groung-glass opacification throughout the lung, interstitial thickening, cystic changes371 monthNoneYesDied at 4 monthsMaleSplice site deletion c.6670-1delGSeveral episodes of profound desaturationBilateral dependent and subsegmental atelectasis, scattered opacity, interstitial thickening32day of live 1NoneYes11 months, home oxigenOur caseMaleMosaic frameshift mutation c.7391_7403del; (p.Val2464Alafs\*5)Progressive lung diseaseLobar emphysema of the left upper lobe and a subsegmental atelectasis and areas of air trapping into the lower lobe3732 daysLeft lobectomy\
TracheostomyYes15 months\
Mechanical ventilation*FLNA* Filamin A; PNVH periventricular nodular heterotopia; CT computed tomography; PDA patent ductus arteriosus; ND Not provided

In these patients, the presentation of respiratory failure occurred at a median age of 1 month (range, birth to 72 months). However, one reported patient developed progressive obstructive lung disease at the age of 38 years \[[@CR20]\]. The clinical presentation of lung involvement was variable, ranging from multiple episodes of intercurrent pulmonary infections \[[@CR13]\], to progressive severe pulmonary disease \[[@CR13], [@CR14], [@CR16]--[@CR18], [@CR20]\]. A variable outcome and management course were reported in the previously reported cases. In a limited number of patients, supportive therapy was successful \[[@CR13], [@CR16], [@CR17], [@CR19]\]. Surgical intervention in the form of lobar resection \[[@CR2], [@CR9], [@CR13]\], as in our case, or lung transplantation, may be indicated in severe cases where supportative therapies are not successful \[[@CR14], [@CR20]\].

The pulmonary growth abnormality associated with FLNA deficiency consists of multilobar overinflation predominantly affecting the upper and lower lobes, with coarse septal thickening and varying lower lobe atelectasis with pruning of the peripheral pulmonary vasculature \[[@CR27]\]. The role of FLNA in the development of lung disease is still not well elucidated. Considering that during respiration the lungs are subjected to mechanical forces and because FLNA plays important role in cell mechanosensing and mechanotransduction, abnormal FLNA interactions could affect pulmonary viscoelastic properties and disturb alveolar formation and growth \[[@CR14], [@CR28]\]. However, a role in T cell activation, interleukin production \[[@CR29]\], inflammatory signaling \[[@CR30]\] and interaction with the cystic fibrosis transmembrane conductance regulator \[[@CR31]\] has also been proposed. Furthermore, the crucial role of FLNA action in mesenchymal migration, should not be excluded. Alterations in mesenchymal properties could be directly related to defects in cell migration during embryonic development and in pulmonary damage described in FLNA-defective patients \[[@CR32]\]. Further studies are needed to investigate the functional role of tissue-resident lung mesenchymal stem cells in health and disease. Considering the successful use of stem cell therapy in the treatment of chronic progressive pulmonary disease in adults \[[@CR31]--[@CR37]\], future perspective stem cell treatment also in FLNA mutation-related lung disorders in children should be investigated. In conclusion, we report a novel mosaic loss-of-function variant of the *FLNA* gene associated with a severe lung disorder and PNVH. The lung disorder led to respiratory failure during infancy and these pulmonary complications may be the first sign of this disorder. Early recognition with thoracic imaging is important to guide genetic testing, neuroimaging and to define optimal timing of potential therapies, such as lung transplant in progressive lung disease \[[@CR14]\].

CLE

:   Congenital lobar emphysema

CT

:   Computed tomography

FLNA

:   Filamin A

PVNH

:   Periventricular nodular heterotopia

The authors thank Dr. L. Kelly for English revision of the manuscript.

Funding {#FPar1}
=======

The authors declare that they did not receive any source of funding for the preparation of the manuscript.

Availability of data and materials {#FPar2}
==================================

This section is not applicable.

GP, GC management of the patient, drafting the article, critical revision of the article; MC, AP, MPP, CC management of the patient, critical revision of the article; EA, AN, MP genetic evaluation, drafting the article, critical revision of the article; RB histological evaluation; VC drafting the article, literature review, critical revision of the article. All authors read and approved the final manuscript.

Ethical approval and consent to participate {#FPar3}
===========================================

The study was performed according to the Declaration of Helsinki. Written informed consent was obtained from the patient's parents for publication of this case report and accompanying images.

Consent for publication {#FPar4}
=======================

Written informed consent was obtained from the patient's parents for publication of this case report and accompanying images.

Competing interests {#FPar5}
===================

The authors have no competing interests to declare.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
